Skip directly to search Skip directly to A to Z list Skip directly to navigation Skip directly to page options Skip directly to site content
Cancer PHGKB

Specific PHGKB|Cancer|PHGKB
Last Posted: Dec 04, 2021
spot light Spotlight

Studies Focus on Testing Family Members of Cancer Gene Carriers
NCI, November 2021

NCI released a funding opportunity to test a “traceback” strategy, where researchers are finding the women who were previously diagnosed with ovarian cancer, communicating with them (or with their family members if they have died), and offering genetic testing. Traceback is a unique approach to genetic testing because the idea is to work backwards and find previously diagnosed cases to test to improve the detection of families at risk. Three grants using different approaches for traceback testing were funded for 4 years; projects are expected to be completed in 2023. The overall goal is to evaluate the best way to communicate sensitive genetic information to ovarian cancer patients and their immediate family members. Challenges associated with privacy laws and ethical concerns, differences in cultural traditions, and medical literacy are taken into account.

Germline breast cancer susceptibility genes, tumor characteristics, and survival
PJ Ho et al, Genome Medicine, December 2, 2021

Mutations in certain genes are known to increase breast cancer risk. We study the relevance of rare protein-truncating variants (PTVs) that may result in loss-of-function in breast cancer susceptibility genes on tumor characteristics and survival in 8852 breast cancer patients of Asian descent. We found that PTV9genes carriership is associated with more aggressive tumors. Variants in other genes might be associated with the survival of breast cancer patients.

A polygenic risk score for multiple myeloma risk prediction.
Canzian Federico et al. European journal of human genetics : EJHG 2021 11

Using 2361 MM cases and 1415 controls from the International Multiple Myeloma rESEarch (IMMEnSE) consortium, we computed a weighted and an unweighted PRS. We observed associations with MM risk with OR?=?3.44, 95% CI 2.53–4.69, p?=?3.55?×?10-15 for the highest vs. lowest quintile of the weighted score, and OR?=?3.18, 95% CI 2.1?=?34–4.33, p?=?1.62?×?10-13 for the highest vs. lowest quintile of the unweighted score. We found a convincing association of a PRS generated with 23 SNPs and risk of MM.

Insights Into Immune-Mediated Disease and Cancer Risk-Delivering on the Promise of UK Biobank Big Data.
Stewart Douglas R et al. JAMA oncology 2021 12

Large, longitudinal data sets derived from the electronic health records are powerful tools for discovery. A recent study extracted from the big data provided by the UK Biobank clinically and scientifically useful insights and estimates of cancer risk associated with immune-mediated disease.


news Latest News and Publications
A Polygenic Risk Score Predicts Incident Prostate Cancer Risk in Older Men but Does Not Select for Clinically Significant Disease. External Web Site Icon
Bakshi Andrew et al. Cancers 2021 13(22)
Community oncologists' perceptions and utilization of large-panel genomic tumor testing. External Web Site Icon
Anderson Eric C et al. BMC cancer 2021 21(1) 1273
Considerations on the identification and management of metastatic prostate cancer patients with DNA repair gene alterations in the Canadian context. External Web Site Icon
Kolinsky Michael P et al. Canadian Urological Association journal = Journal de l'Association des urologues du Canada 2021
Construction and validation of a novel aging-related gene signature and prognostic nomogram for predicting the overall survival in ovarian cancer. External Web Site Icon
Liu Lixiao et al. Cancer medicine 2021
Feasibility of a Traceback Approach for Using Pathology Specimens to Facilitate Genetic Testing in the Genetic Risk Analysis in Ovarian Cancer (GRACE) Study Protocol. External Web Site Icon
Kauffman Tia L et al. Journal of personalized medicine 2021 11(11)
Fine-needle Aspiration Washout Precipitation Specimens: An Acceptable Supplement to Genetic Mutation Detection of Thyroid Nodules. External Web Site Icon
Cui Yongmei et al. Technology in cancer research & treatment 2021 2015330338211057982
First Nationwide Molecular Screening Program in Spain for Patients With Advanced Breast Cancer: Results From the AGATA SOLTI-1301 Study. External Web Site Icon
Pernas Sonia et al. Frontiers in oncology 2021 11744112
Identification of NSP3 (SH2D3C) as a Prognostic Biomarker of Tumor Progression and Immune Evasion for Lung Cancer and Evaluation of Organosulfur Compounds from Allium sativum L. as Therapeutic Candidates. External Web Site Icon
Yeh Yuan-Chieh et al. Biomedicines 2021 9(11)
Machine Learning for Recurrence Prediction of Gynecologic Cancers Using Lynch Syndrome-Related Screening Markers. External Web Site Icon
Kim Byung Wook et al. Cancers 2021 13(22)
Next generation diagnostic algorithm in non-small cell lung cancer predictive molecular pathology: The KWAY Italian multicenter cost evaluation study. External Web Site Icon
Pisapia Pasquale et al. Critical reviews in oncology/hematology 2021 103525

More


Disclaimer: Articles listed in the Public Health Knowledge Base are selected by the CDC Office of Public Health Genomics to provide current awareness of the literature and news. Inclusion in the update does not necessarily represent the views of the Centers for Disease Control and Prevention nor does it imply endorsement of the article's methods or findings. CDC and DHHS assume no responsibility for the factual accuracy of the items presented. The selection, omission, or content of items does not imply any endorsement or other position taken by CDC or DHHS. Opinion, findings and conclusions expressed by the original authors of items included in the update, or persons quoted therein, are strictly their own and are in no way meant to represent the opinion or views of CDC or DHHS. References to publications, news sources, and non-CDC Websites are provided solely for informational purposes and do not imply endorsement by CDC or DHHS.

TOP